Moderna Says New Covid-19 Vaccine Generates Strong Response Against Variant

Dow Jones

2025/09/16

By Nicholas G. Miller

Moderna said the 2025-2026 formula of its Covid-19 vaccine produced a strong immune response against the dominant LP.8.1 variant.

The company said a preliminary analysis from a phase four clinical trial showed the new formula of its Spikevax vaccine generated an eight-fold increase in LP.8.1-neutralizing antibodies.

No new safety concerns of the vaccine were identified.

Spikevax is approved for individuals six months through 64 years of age with at least one underlying condition that puts them at higher risk for Covid-19, and all adults 65 years and older.

The company said CDC data from U.S. wastewater shows Covid-19 activity is high, with LP.8.1 and its familial strains continuing to dominate.

Earlier this month, Pfizer and BioNTech said the updated formula of their Covid-19 vaccine generated a strong response against the variant.

A phase three trial showed a four-fold increase in LP.8.1-neutralizing antibodies.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

September 16, 2025 06:30 ET (10:30 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2567093621"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567093621\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567093621?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567093621","market":"nz","top_or_hot":-1,"title":"Moderna Says New Covid-19 Vaccine Generates Strong Response Against Variant","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> said the 2025-2026 formula of its Covid-19 vaccine produced a strong immune response against the dominant LP.8.1 variant. \n</p>\n<p>\n  The company said a preliminary analysis from a phase four clinical trial showed the new formula of its Spikevax vaccine generated an eight-fold increase in LP.8.1-neutralizing antibodies. \n</p>\n<p>\n  No new safety concerns of the vaccine were identified. \n</p>\n<p>\n  Spikevax is approved for individuals six months through 64 years of age with at least one underlying condition that puts them at higher risk for Covid-19, and all adults 65 years and older. \n</p>\n<p>\n  The company said CDC data from U.S. wastewater shows Covid-19 activity is high, with LP.8.1 and its familial strains continuing to dominate. \n</p>\n<p>\n  Earlier this month, Pfizer and BioNTech said the updated formula of their Covid-19 vaccine generated a strong response against the variant. \n</p>\n<p>\n  A phase three trial showed a four-fold increase in LP.8.1-neutralizing antibodies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 16, 2025 06:30 ET (10:30 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Says New Covid-19 Vaccine Generates Strong Response Against Variant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Says New Covid-19 Vaccine Generates Strong Response Against Variant\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-16 18:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> said the 2025-2026 formula of its Covid-19 vaccine produced a strong immune response against the dominant LP.8.1 variant. \n</p>\n<p>\n  The company said a preliminary analysis from a phase four clinical trial showed the new formula of its Spikevax vaccine generated an eight-fold increase in LP.8.1-neutralizing antibodies. \n</p>\n<p>\n  No new safety concerns of the vaccine were identified. \n</p>\n<p>\n  Spikevax is approved for individuals six months through 64 years of age with at least one underlying condition that puts them at higher risk for Covid-19, and all adults 65 years and older. \n</p>\n<p>\n  The company said CDC data from U.S. wastewater shows Covid-19 activity is high, with LP.8.1 and its familial strains continuing to dominate. \n</p>\n<p>\n  Earlier this month, Pfizer and BioNTech said the updated formula of their Covid-19 vaccine generated a strong response against the variant. \n</p>\n<p>\n  A phase three trial showed a four-fold increase in LP.8.1-neutralizing antibodies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 16, 2025 06:30 ET (10:30 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1057294990.SGD","symbol_name":"Blackrock World Healthscience A2 SGD-H","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2567093621","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567093621","pubTimestamp":1758018600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Moderna said the 2025-2026 formula of its Covid-19 vaccine produced a strong immune response against the dominant LP.8.1 variant.The company said a preliminary analysis from a phase four clinical trial showed the new formula of its Spikevax vaccine generated an eight-fold increase in LP.8.1-neutralizing antibodies.No new safety concerns of the vaccine were identified.Spikevax is approved for individuals six months through 64 years of age with at least one underlying condition that puts them at higher risk for Covid-19, and all adults 65 years and older.The company said CDC data from U.S. wastewater shows Covid-19 activity is high, with LP.8.1 and its familial strains continuing to dominate.Earlier this month, Pfizer and BioNTech said the updated formula of their Covid-19 vaccine generated a strong response against the variant.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4534":"瑞士信贷持仓","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999002232.USD":"Allianz Global High Payout USD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4535":"淡马锡持仓","BK4592":"伊斯兰概念","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","BK4548":"巴美列捷福持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","MRNA":"Moderna, Inc.","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","BNTX":"BioNTech SE","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4551":"寇图资本持仓","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4007":"制药","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","BK4501":"段永平概念","SG9999001176.USD":"United Global Healthcare Acc USD"},"translate_title":"Moderna表示新的Covid-19疫苗对变种产生了强烈反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1.5,"MRNA":0.9},"content_text":"By Nicholas G. Miller \n\n\n \n\n\nModerna said the 2025-2026 formula of its Covid-19 vaccine produced a strong immune response against the dominant LP.8.1 variant. \n\n\n  The company said a preliminary analysis from a phase four clinical trial showed the new formula of its Spikevax vaccine generated an eight-fold increase in LP.8.1-neutralizing antibodies. \n\n\n  No new safety concerns of the vaccine were identified. \n\n\n  Spikevax is approved for individuals six months through 64 years of age with at least one underlying condition that puts them at higher risk for Covid-19, and all adults 65 years and older. \n\n\n  The company said CDC data from U.S. wastewater shows Covid-19 activity is high, with LP.8.1 and its familial strains continuing to dominate. \n\n\n  Earlier this month, Pfizer and BioNTech said the updated formula of their Covid-19 vaccine generated a strong response against the variant. \n\n\n  A phase three trial showed a four-fold increase in LP.8.1-neutralizing antibodies. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 16, 2025 06:30 ET (10:30 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}